Literature DB >> 447830

Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

W A Muller, M Berger, P Suter, H J Cüppers, J Reiter, T Wyss, P Berchtold, F H Schmidt, J P Assal, A E Renold.   

Abstract

Glucogon immunoreactivity (IRG) was measured in plasma of duodenopancreatectomized subjects with a nonspecific (K-4023) and a specific (30-K) glucagon antiserum. After an overnight fast, plasma IRG (K-4023) was significantly (P < 0.05) higher in the subjects without pancreas, averaging 782+/-79 (SEM) pgeq/ml, than in the controls (482+/-80 pgeq/ml). IRG (30-K) of 162+/-68 pg/ml did not change during an infusion of arginine (450 mg/kg per 40 min). Insulin deprivation during 3 d in one patient did not restore the IRG response to arginine as reported in depancreatized dogs.Bio-Gel P-30 column chromatography revealed that virtually all IRG (30-K) measured in whole plasma was of different molecular weight than glucagon, and primarily of a mol wt >/= 40,000. Intravenous arginine did not significantly alter the chromatographic pattern of these plasmas. Thus, as postulated by others, duodeno-pancreatectomized humans have virtually no circulating 3,500-dalton glucagon. Hence, the presence of 3,500-dalton glucagon in plasma is not a condition for the diabetic state. It might, nevertheless, when present in normal or excessive amounts, worsen the metabolic state of diabetic patients. Among 14 amino acids measured in plasma of these patients, the concentrations of alanine, serine, ornithine, and arginine were significantly (P < 0.05) elevated to approximately twice that of normal: alanine and serine are both substrates for gluconeogenesis, whereas ornithine and arginine are involved in the formation of urea, the second product of hepatic gluconeogenesis. As the concentrations of branched chain amino acids were not grossly altered, it is hypothesized that this amino acid pattern is a consequence of glucagon deficiency rather than secondary to the diabetic state of these patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447830      PMCID: PMC372022          DOI: 10.1172/JCI109381

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  LIFE WITHOUT A PANCREAS.

Authors:  A G WHITFIELD; C W CRANE; J M FRENCH; T J BAYLEY
Journal:  Lancet       Date:  1965-03-27       Impact factor: 79.321

2.  Blood amine acid levels in patients with insulin excess (functioning insulinoma) and insulin deficiency (diabetic ketosis).

Authors:  M Berger; H Zimmermann-Telschow; P Berchtold; H Drost; W A Müller; F A Gries; H Zimmermann
Journal:  Metabolism       Date:  1978-07       Impact factor: 8.694

Review 3.  Physiology and pathophysiology of glucagon.

Authors:  R H Unger; L Orci
Journal:  Physiol Rev       Date:  1976-10       Impact factor: 37.312

4.  Characteristics of tissue IRGs in the dog.

Authors:  C B Srikant; K McCorkle; R H Unger
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

5.  The spontaneously diabetic Wistar rat (the "BB" rat). Studies prior to and during development of the overt syndrome.

Authors:  A F Nakhooda; A A Like; C I Chappel; C N Wei; E B Marliss
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

6.  Circulating glucagon. Plasma profiles and metabolism in health and disease.

Authors:  J B Jaspan; A H Rubenstein
Journal:  Diabetes       Date:  1977-09       Impact factor: 9.461

7.  Effects of exogenous hyperglucagonemia in insulin-treated diabetics.

Authors:  P Raskin; R H Unger
Journal:  Diabetes       Date:  1977-11       Impact factor: 9.461

8.  Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs. A quantitative assessment of secretion rates and anatomical delineation of sources.

Authors:  W A Muller; L Girardier; J Seydoux; M Berger; A E Renold; M Vranic
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Persistent metabolic abnormalities in diabetes in the absence of glucagon.

Authors:  A J Barnes; S R Bloom; K Mashiter; K G Alberti; P Smythe; D Turnell
Journal:  Diabetologia       Date:  1977-01       Impact factor: 10.122

10.  Ketoacidosis in pancreatectomized man.

Authors:  A J Barnes; S R Bloom; K Goerge; G M Alberti; P Smythe; F P Alford; D J Chisholm
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

View more
  16 in total

1.  Correlation between pancreatic endocrine and exocrine function and characteristics of pancreatic endocrine function in patients with diabetes mellitus owing to chronic pancreatitis.

Authors:  T Nakamura; K Imamura; K Takebe; A Terada; Y Arai; Y Tandoh; N Yamada; M Ishii; K Machida; T Suda
Journal:  Int J Pancreatol       Date:  1996-12

2.  Japanese Gastroenterology Society. Proceedings of the 71st general meeting. Sapporo, Japan, May 22-24, 1985. Abstracts.

Authors: 
Journal:  Gastroenterol Jpn       Date:  1986-02

3.  Hyperalaninaemia is an early feature of diabetes secondary to total pancreatectomy.

Authors:  S Del Prato; S Vigili de Kreutzenberg; R Trevisan; E Duner; A Avogaro; R Nosadini; U Baccaglini; C Tremolada; A Tiengo
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

4.  Paradoxical elevations of plasma glucagon levels in patients after pancreatectomy or gastrectomy.

Authors:  K Ohtsuka; Y Nimura; K Yasui
Journal:  Jpn J Surg       Date:  1986-01

5.  Effects of glucagon on plasma amino acids.

Authors:  G Boden; I Rezvani; O E Owen
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

6.  Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.

Authors:  Jinrang Kim; Haruka Okamoto; ZhiJiang Huang; Guillermo Anguiano; Shiuhwei Chen; Qing Liu; Katie Cavino; Yurong Xin; Erqian Na; Rachid Hamid; Joseph Lee; Brian Zambrowicz; Roger Unger; Andrew J Murphy; Yan Xu; George D Yancopoulos; Wen-Hong Li; Jesper Gromada
Journal:  Cell Metab       Date:  2017-06-06       Impact factor: 27.287

7.  Glucagon deficiency and hyperaminoacidemia after total pancreatectomy.

Authors:  G Boden; R W Master; I Rezvani; J P Palmer; T E Lobe; O E Owen
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

8.  Plasma pancreatic glucagon in pancreatic and primary diabetes, and liver cirrhosis: application of a correction to the radioimmunoassay for pancreatic glucagon.

Authors:  N Okumura; T Hayakawa; K Yasui; A Noda; T Kondo; K Otsuka; Y Nimura
Journal:  Gastroenterol Jpn       Date:  1982

9.  Metabolic consequences of (regional) total pancreatectomy.

Authors:  C M Dresler; J G Fortner; K McDermott; D R Bajorunas
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

10.  Glucagon and carbohydrate disorder in a totally pancreatectomized man (a study with the aid of an artificial endocrine pancreas).

Authors:  F Santeusanio; M Massi-Benedetti; G Angeletti; G Calabrese; A Bueti; P Brunetti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.